@tamsenfadal's hormone therapy claims, fact-checked

Tamsen Fadal's TikTok video makes several claims about hormone replacement therapy for menopause, covering estrogen, progesterone, and testosterone. While she touches on legitimate aspects of menopausal hormone therapy, some of her statements need context and clarification based on current clinical evidence.

What does this video actually claim?

Fadal presents hormone therapy as a comprehensive solution for menopausal symptoms, emphasizing the benefits of estrogen, progesterone, and testosterone replacement. She suggests these hormones can address multiple symptoms and improve quality of life during menopause.

The video positions hormone therapy as generally beneficial without diving deep into the nuanced risk-benefit analysis that defines modern menopausal care. She doesn't mention the timing hypothesis or the significant safety considerations that emerged from landmark studies like the Women's Health Initiative.

Her presentation focuses on the positive aspects of hormone therapy without adequately addressing the individual risk assessment that should guide treatment decisions.

Does the science support hormone therapy benefits?

Yes, but with important caveats. The NICE guidelines (2015, updated 2019) support hormone therapy as first-line treatment for vasomotor symptoms in women under 60 or within 10 years of menopause. Estrogen therapy reduces hot flashes by 75% compared to placebo in most trials.

For testosterone, the evidence is more limited. The Global Consensus Statement on Menopausal Hormone Therapy (2023) supports testosterone for hypoactive sexual desire disorder in postmenopausal women already on estrogen therapy.

However, the WHI study (Rossouw et al., JAMA, 2002) showed combined estrogen-progestin therapy increased breast cancer risk by 26% and stroke risk by 41% in older postmenopausal women. The timing and type of therapy matter significantly.

What context is missing from her claims?

Fadal doesn't adequately address the timing hypothesis, which is central to modern hormone therapy prescribing. The WHI reanalysis (Manson et al., JAMA, 2017) showed women who started hormone therapy within 10 years of menopause had different risk profiles than those who started later.

She also glosses over the fact that testosterone therapy for women isn't FDA-approved in the United States. Most prescribing is off-label using male formulations or compounded preparations.

The video lacks discussion of contraindications. Women with a history of breast cancer, blood clots, or stroke typically shouldn't use systemic hormone therapy. The American College of Obstetricians and Gynecologists emphasizes individualized risk assessment.

What should you know about menopausal hormone therapy?

Hormone therapy works best when started early in menopause for women without contraindications. The absolute risks are generally low for healthy women under 60, but individual factors like family history and personal medical history matter significantly.

Estrogen therapy alone (for women without a uterus) carries lower risks than combined estrogen-progestin therapy. The North American Menopause Society recommends using the lowest effective dose for the shortest duration needed.

For testosterone, current evidence supports its use specifically for sexual desire issues, not as a general wellness intervention. The International Menopause Society emphasizes that testosterone should be prescribed alongside estrogen therapy, not alone.